Artiva Biotherapeutics (ARTV) Receivables - Other (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Receivables - Other of -$67000.0 for Q1 2026, down 128.63% year-over-year from $234000.0 in Q1 2025, and down 458.33% quarter-over-quarter from -$12000.0 in Q4 2025.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) Receivables - Other (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Receivables - Other for 4 consecutive years, with -$67000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other fell 128.63% year-over-year to -$67000.0; the TTM figure through Mar 2026 stood at $115000.0 (down 50.85% YoY), while the FY2025 annual figure was -$79000.0, up 86.33% from the prior year.
- Receivables - Other declined to -$67000.0 in Q1 2026 per ARTV's latest filing, from -$12000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $892000.0 in Q2 2024 and bottomed at -$67000.0 in Q1 2026.
- Historically, Receivables - Other has averaged $260454.5 across 4 years, with a median of $132000.0 in 2024.
- On a YoY basis, Receivables - Other climbed as much as 30.0% in 2025 and fell as far as 185.71% in 2025.
- Artiva Biotherapeutics' Receivables - Other stood at $724000.0 in 2023, then plunged by 98.07% to $14000.0 in 2024, then plunged by 185.71% to -$12000.0 in 2025, then plunged by 458.33% to -$67000.0 in 2026.
- Business Quant data shows ARTV's Receivables - Other at -$67000.0 in Q1 2026, -$12000.0 in Q4 2025, and $79000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 141,000.00 |
| Mar 31, 2026 | -67,000.00 |
| Dec 31, 2025 | -12,000.00 |
| Sep 30, 2025 | 79,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 234,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 892,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | 724,000.00 |
| Sep 30, 2023 | 659,000.00 |